Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential
Current Issues in Molecular Biology · 05.09.2025 · 47 (9) · 724
DOI: 10.3390/cimb47090724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 05.09.2025. Verfasst von Alejandro Borrego-Ruiz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Psicología Social y de las Organizaciones, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 298 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Accumulating evidence underscores the potential role of the gut microbiome in the pathogenesis of Alzheimer’s disease, but much remains to be clarified. This review examines current evidence linking gut microbiome dysbiosis to Alzheimer’s disease, focusing on microbial metabolomes and their mechanistic role, as well as on the potential of therapeutic approaches targeting the gut microbiome.
Methods
A narrative, non-systematic examination of the literature was conducted to provide a comprehensive overview of the subject under examination. Database searches were performed in PubMed, Scopus, and Web of Science between June and July 2025.
Results
Alzheimer’s disease is linked to reduced gut microbial diversity and altered bacterial taxa. Gut microbiome shifts correlate with inflammation and may drive Alzheimer’s disease progression via the microbiota–gut–brain axis. Microbial amyloids and bacterial products can cross both the intestinal and blood–brain barrier, triggering neuroinflammation and promoting amyloid and tau pathologies. Short-chain fatty acids produced by the gut microbiome regulate neuroinflammation, lipid metabolism, and gene expression, impacting Alzheimer’s disease pathology. Therapeutics targeting the gut microbiome, including probiotics, prebiotics, and fecal microbiota transplantation, show promise in modulating neuroinflammation, reducing amyloid and tau pathology, and improving cognitive function in Alzheimer’s disease.
Conclusions
The gut microbiome significantly influences Alzheimer’s disease pathogenesis, and its modulation offers potential to slow progression. However, further research is required to validate effective clinical interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Psicología Social y de las Organizaciones, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain.
- Departamento de Microbiología, Universidad de Málaga, 29071 Málaga, Spain.
ORCID-Profile: Alejandro Borrego-Ruiz, Juan J Borrego
Zitieren
APA
Borrego-Ruiz, A., & Borrego, J. J. (2025). Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential. Current Issues in Molecular Biology, 47(9), 724. https://doi.org/10.3390/cimb47090724
Vancouver
Borrego-Ruiz A, Borrego JJ. Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential. Current Issues in Molecular Biology. 2025;47(9):724. doi:10.3390/cimb47090724
BibTeX
@article{BorregoRuiz2025,
author = {Borrego-Ruiz, Alejandro and Borrego, Juan J},
title = {Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential},
journal = {Current Issues in Molecular Biology},
year = {2025},
volume = {47},
number = {9},
pages = {724},
doi = {10.3390/cimb47090724}
}
EUVIMED